Hepatology: New At Healio
High prevalence of HCV found in baby Boomers via emergency room screening
SSRIs may reduce treatment-associated depression in HCV patients
Nov 12
Hou XJ. PLoS One. 2013;doi:10.1371/journal.pone.0076799.
Prophylactic use of selective serotonin reuptake inhibitors may significantly reduce the incidence of depression associated with pegylated interferon alfa-2a or 2b with ribavirin combination treatment for chronic hepatitis C, researchers from China reported.
Although pegylated interferon alfa-2a or alfa 2b (Peg-IFN a-2a or a-2b) with ribavirin is considered to be the most effective regimen for chronic hepatitis, the treatment is associated with “an approximately 70% incidence of mild to moderate depressive syndromes and 20% to 40% incidence of major depression” in patients with HCV infection, according to the researchers.
More »
Late relapse after SVR may not be new HCV infection
Nov 11
Hara K. J Infect Dis. 2013;doi:10.1093/infdis/jit541.
Patients with hepatitis C who relapse after achieving sustained virological response may be having a relapse of the initial infection rather than a reinfection with a different strain, recent data published in the Journal of Infectious Diseases suggest.
“In a few individuals, hepatitis C has found a sanctuary site and can remain dormant for a length of time,” Theo Heller, MD, chief of the translational hepatology unit at the Liver Diseases Branch of the National Institute of Diabetes & Digestive & Kidney Diseases, told Infectious Disease News. “This is important both biologically and clinically, even in the approaching era of direct-acting antivirals, where relapse may still be a problem. We already know it can and does occur.”
More »
Ongoing phase 2 trial finds RVR from all-oral regimen for HCV patients
November 11, 2013
WASHINGTON — An investigational, all-oral combination of protease inhibitor faldaprevir, non-nucleoside NS5B inhibitor deleobuvir and NS5A inhibitor PPI-668 with and without ribavirin has consistently demonstrated rapid virologic response among the hepatitis C genotype 1a population, a speaker said here.
“On a preliminary basis, it looks like we have another three-drug combo that’s active in the harder-to-treat [HCV] genotype 1a population,” Jacob P. Lalezari, MD, of the University of California, San Francisco, School of Medicine and director of Quest Clinical Research, said in discussing a late-breaking poster at The Liver Meeting.
More »
Additional headlines from The Liver Meeting 2013 @ Healio
Meeting News Coverage
Gamma-GT levels may predict HCC risk in noncirrhotic patients after SVR
November 8, 2013
Meeting News CoverageVideo
Breath analysis may offer noninvasive means to diagnose alcoholic hepatitis
November 8, 2013
Meeting News CoverageVideo
Triple therapy with sofosbuvir yields high SVR rates among cirrhotic patients with HCV
November 7, 2013
Meeting News CoverageVideo
ARF6 gene associated with biliary atresia
November 7, 2013
Meeting News Coverage
Public education on acetaminophen dangers vitally important
November 6, 2013
Meeting News Coverage
Interferon/ribavirin-free triple therapy highly effective for chronic HCV genotype 1
November 5, 2013
Meeting News Coverage
Immunosuppression, EVR predictive of SVR in liver transplant recipients with HCV
November 5, 2013
Meeting News Coverage
Severe fibrosis, not NAS, predicted disease-specific mortality in NAFLD
November 5, 2013
Meeting News Coverage
ED screening identifies previously undiagnosed patients with HCV
November 5, 2013
Meeting News Coverage
Medication trade-offs significantly associated with readmissions after liver transplant
November 5, 2013
Meeting News Coverage
No benefit from post-HPE corticosteroid therapy in infants with biliary atresia
November 4, 2013
Meeting News Coverage
Hepatotoxicity from herbal, dietary supplements rising
November 4, 2013
Meeting News CoverageVideo
3-D liver reproduction offers new planning, educational opportunities
November 4, 2013
Meeting News Coverage
Longer transplant waits for HCC patients may be beneficial
November 4, 2013
Meeting News CoverageVideo
Cell-based assay may predict liver transplant rejection in children
November 3, 2013
Meeting News Coverage
Accuracy, reproducibility of liver disease assessment poor in morbidly obese patients
November 3, 2013
Meeting News Coverage
Liver Meeting speaker: HCC exceptions contributing to MELD inflation, transplant inequity
November 3, 2013
Meeting News Coverage
Bleeding complications predict, but don’t cause poor outcomes in patients with acute liver failure
November 2, 2013
Meeting News Coverage
Fatty liver disease may overtake HCV as key cause of liver transplant, AASLD president says
November 2, 2013
No comments:
Post a Comment